Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension

NCT00522925 is registered in ClinicalTrials.gov with Ligand Pharmaceuticals as lead sponsor.

NCT NCT00522925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00522925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension
Lead sponsor
Ligand Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
May 31, 2008
Enrollment
280 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension